Operating within Inception Sciences' build-to-buy model partnership with Versant Ventures, Inception IBD benefits from access to integrated chemistry, biology, and DMPK capabilities. The company has secured strategic backing from major pharmaceutical players, including a notable collaboration with Celgene (announced December 2015) to advance IBD therapeutics, positioning it as a disciplined discovery player in the specialty pharma space.
Cyborg Score Rationale
Inception IBD demonstrates solid execution within a focused therapeutic area with academic backing and institutional validation through Versant and Celgene partnerships. However, limited public visibility on recent clinical progress, competitive pressure from established IBD players, and reliance on the Inception Sciences model constrain upside potential.
Top Insights
Leverages Inception Sciences' proven drug discovery engine and partnership model for faster time-to-value
Strategic collaboration with Celgene (December 2015) provides pharmaceutical partnership, funding, and potential acquisition pathway
Focused therapeutic niche (IBD small molecules) with high unmet medical need
Limited public information on clinical-stage programs or recent milestones as of mid-2026
Named Competitors
Rinvoq — JAK inhibitor for ulcerative colitis and Crohn's disease
Stelara — Anti-IL-12/IL-23 biologic for IBD
Skyrizi — IL-23 antagonist for ulcerative colitis
IBD Therapeutics Portfolio — Diversified IBD and immunology portfolio including Celgene assets
Recent Developments
(December 2015) Completed Series A financing led by Versant Ventures; bolstered management team
(December 2015) Announced strategic collaboration with Celgene for development of novel IBD therapeutics